Head-To-Head Contrast: Histogenics Corporation (HSGX) versus Its Competitors
Histogenics Corporation (NASDAQ: HSGX) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Histogenics Corporation to similar businesses based on the strength of its valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and profitability.
Insider and Institutional Ownership
50.1% of Histogenics Corporation shares are held by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceuticals” companies are held by institutional investors. 23.8% of Histogenics Corporation shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Histogenics Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Histogenics Corporation Competitors||-2,389.76%||-60.07%||-7.42%|
Valuation and Earnings
This table compares Histogenics Corporation and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Histogenics Corporation||N/A||-$16.20 million||-1.39|
|Histogenics Corporation Competitors||$8.17 billion||$1.09 billion||163.44|
Histogenics Corporation’s competitors have higher revenue and earnings than Histogenics Corporation. Histogenics Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Histogenics Corporation has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Histogenics Corporation’s competitors have a beta of 36.54, indicating that their average share price is 3,554% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Histogenics Corporation and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Histogenics Corporation Competitors||858||3777||6721||178||2.54|
Histogenics Corporation currently has a consensus price target of $3.75, indicating a potential upside of 95.31%. As a group, “Pharmaceuticals” companies have a potential upside of 26.40%. Given Histogenics Corporation’s stronger consensus rating and higher possible upside, equities analysts clearly believe Histogenics Corporation is more favorable than its competitors.
About Histogenics Corporation
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.
Receive News & Stock Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related stocks with our FREE daily email newsletter.